<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091377</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000389129</org_study_id>
    <secondary_id>NOVOGEN-NV06-037</secondary_id>
    <secondary_id>YALE-HIC-26423</secondary_id>
    <nct_id>NCT00091377</nct_id>
  </id_info>
  <brief_title>Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <official_title>Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEI Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEI Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Phenoxodiol may help&#xD;
      cisplatin and paclitaxel kill more tumor cells by making tumor cells more sensitive to the&#xD;
      drugs.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying the side effects of phenoxodiol when&#xD;
      given together with either cisplatin or paclitaxel and to see how well they work in treating&#xD;
      patients with recurrent late-stage ovarian epithelial cancer, fallopian tube cancer, or&#xD;
      primary peritoneal cancer that has not responded to treatment with drugs such as paclitaxel,&#xD;
      docetaxel, cisplatin, or carboplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the safety and tolerability of phenoxodiol combined with cisplatin or paclitaxel&#xD;
           in patients with recurrent late-stage ovarian epithelial, fallopian tube, or primary&#xD;
           peritoneal cancer that is refractory or resistant to platinum and/or taxane drugs.&#xD;
&#xD;
        -  Compare, preliminarily, tumor response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is an open-label, randomized, multicenter study. Patients are randomized to 1&#xD;
      of 2 treatment arms according to medical history.&#xD;
&#xD;
        -  Arm I: Patients receive phenoxodiol IV over 10 minutes on days 1 and 2 and cisplatin IV&#xD;
           over 1 hour on day 2.&#xD;
&#xD;
        -  Arm II: Patients receive phenoxodiol as in arm I and paclitaxel IV over 1 hour on day 2.&#xD;
&#xD;
      In both arms, treatment repeats every 6 weeks for up to 8 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at 12, 24, 36, and 48 weeks or at the end of study participation.&#xD;
&#xD;
      Patients are followed at 6 and 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients (20 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Average 6 mo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Average 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surrogate marker of tumor response in terms of plasma protein tNOX</measure>
    <time_frame>Average 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenoxodiol</intervention_name>
    <description>IV 3 mg/kg</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal&#xD;
             cancer&#xD;
&#xD;
               -  Recurrent disease&#xD;
&#xD;
          -  Received no more than 4 prior chemotherapy regimens for this malignancy&#xD;
&#xD;
               -  Considered refractory or resistant to prior taxane (paclitaxel or docetaxel)&#xD;
                  and/or platinum (cisplatin or carboplatin) therapy based on 1 of the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Treatment-free interval &lt; 6 months after platinum or paclitaxel&#xD;
&#xD;
                    -  Disease progression during platinum- or paclitaxel-based therapy&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Measurable disease is defined as at least 1 unidimensionally measurable lesion ≥&#xD;
                  20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Evaluable disease is defined as doubling of CA 125 blood levels within the past 6&#xD;
                  months AND CA 125 level ≥ 2 times upper limit of normal (ULN) within the past&#xD;
                  week&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
               -  Patients with known CNS metastases must have received prior radiotherapy or&#xD;
                  CNS-directed chemotherapy AND have ≥ 4 weeks of stable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  Hematocrit ≥ 28% (transfusion or growth factors allowed)&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0 g/dL (transfusion or growth factors allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  SGOT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No neuropathy (sensory or motor) &gt; grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy for the malignancy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior whole abdominal radiotherapy&#xD;
&#xD;
          -  Concurrent localized radiotherapy allowed for control of local complications not&#xD;
             indicative of general disease progression&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior antineoplastic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior standard therapy for malignant tumor&#xD;
&#xD;
          -  More than 6 months since prior investigational anticancer drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent drugs significantly metabolized by the cytochrome P450 enzymes CYP2C8,&#xD;
             CYP2C9, CYP2C19, and CYP3A4/B1C&#xD;
&#xD;
          -  No concurrent amifostine or other protective agents&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Lancaster</last_name>
    <role>Study Chair</role>
    <affiliation>Kazia Therapeutics Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center at Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Women's Hospital</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kelly MG, Mor G, Husband A, O'Malley DM, Baker L, Azodi M, Schwartz PE, Rutherford TJ. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Int J Gynecol Cancer. 2011 May;21(4):633-9. doi: 10.1097/IGC.0b013e3182126f05.</citation>
    <PMID>21412168</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

